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Abstract
Background and Aims: Psychological stress is a predisposing factor in the onset and exacerbation of important
gastrointestinal diseases including irritable bowel syndrome (IBS) and the inflammatory bowel diseases (IBD). The
pathophysiology of stress-induced intestinal disturbances is known to be mediated by corticotropin releasing factor (CRF)
but the precise signaling pathways remain poorly understood. Utilizing a porcine ex vivo intestinal model, the aim of this
study was to investigate the mechanisms by which CRF mediates intestinal epithelial barrier disturbances.
Methodology: Ileum was harvested from 6–8 week-old pigs, mounted on Ussing Chambers, and exposed to CRF in the
presence or absence of various pharmacologic inhibitors of CRF-mediated signaling pathways. Mucosal-to-serosal flux of
4 kDa-FITC dextran (FD4) and transepithelial electrical resistance (TER) were recorded as indices of intestinal epithelial
barrier function.
Results: Exposure of porcine ileum to 0.05–0.5 mM CRF increased (p,0.05) paracellular flux compared with vehicle controls.
CRF treatment had no deleterious effects on ileal TER. The effects of CRF on FD4 flux were inhibited with pre-treatment of
tissue with the non-selective CRF1/2 receptor antagonist Astressin B and the mast cell stabilizer sodium cromolyn (10
24 M).
Furthermore, anti-TNF-a neutralizing antibody (p,0.01), protease inhibitors (p,0.01) and the neural blocker tetrodotoxin
(TTX) inhibited CRF-mediated intestinal barrier dysfunction.
Conclusion: These data demonstrate that CRF triggers increases in intestinal paracellular permeability via mast cell
dependent release of TNF-a and proteases. Furthermore, CRF-mast cell signaling pathways and increases in intestinal
permeability require critical input from the enteric nervous system. Therefore, blocking the deleterious effects of CRF may
address the enteric signaling of mast cell degranulation, TNFa release, and protease secretion, hallmarks of IBS and IBD.
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Introduction
The gastrointestinal barrier, consisting primarily of intestinal
epithelial cells, mucus layer, and sub-epithelial immune cells,
selectively controls the access of the immense luminal load of
antigens and resident microorganism to the underlying lamina
propria immune tissues [1]. It is well-known that intestinal barrier
function can be adversely affected by acute or chronic psycholog-
ical stress, resulting in increased intestinal permeability [2,3,4,5,6],
a critical event in the onset of clinical symptoms of GI disorders
including irritable bowel syndrome (IBS) and inflammatory bowel
disease (IBD) [7,8,9,10]. Disturbances in intestinal barrier
facilitates bacterial movement from the lumen into the lamina
propria while also critically impairing other vital functions
including absorption of nutrients, transport of ions, secretion
[11,12], motility, and visceral hypersensitivity [13,14]. Although it
is known that stress compromises intestinal barrier function, the
precise mechanisms remain poorly understood.
CRF is a 41 amino acid peptide, produced in the central
nervous system and peripheral tissues [15,16] in response to
stress and has been shown to play a central role in stress-induced
intestinal pathophysiology. CRF activity is mediated by activa-
tion of specific seven transmembrane G-protein coupled recep-
tors (GPCRs) known as CRF1 and CRF2. CRF has been shown
to induce intestinal barrier disturbances in multiple animals and
human tissues models. Several studies have demonstrated that
CRF mediates its effects via mast cell activation [6,11,17]. Upon
activation, mast cells are capable of releasing a variety of pro-
inflammatory mediators, including de novo synthesized media-
tors such as prostaglandins, leukotrienes, and cytokines or
preformed granule-housed mediators including histamine, serine
proteases, tryptase, chymase, and cytokines [18], which pro-
foundly influence intestinal epithelial barrier function; however,
the mast cell mediators and signaling pathways that are
responsible for CRF-mediated intestinal barrier dysfunction have
not been fully elucidated. Here, utilizing a porcine model, we
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39935investigated the mechanisms of CRF-mediated intestinal epithe-
lial barrier dysfunction.
Results
Influence of CRF on Porcine Ileal Intestinal Barrier
Function
We employed an ex vivo Ussing chamber system to investigate
the role of local CRF signaling on intestinal epithelial barrier
function in the porcine ileum. CRF, at concentrations of 0.05 and
0.1 mM, and 0.5 mM induced elevations in FD4 flux across ileal
mucosa compared with vehicle-treated controls (Figure 1). In
contrast, exposure of ileal mucosa to CRF did not influence TER
over the 180 minute time period on the chambers (data not
shown). To confirm that CRF was mediating its effects on
intestinal permeability via CRF receptors, ileal mucosa was pre-
treated with the CRF receptor antagonist, Astressin B (1 mM),
prior to exposure of CRF (0.5 mM). Astressin B prevented CRF-
induced elevations in FD4 flux (Figure 2). Histological analysis
revealed no disruption of intestinal epithelial continuity with CRF
(0.5 mM) treatment (Figure 3) indicating that the effects of CRF
were due to alterations in the paracellular flux pathways rather
than destruction of the epithelium. Immunoflourescence analysis
of the tight junction protein occludin revealed marked disruption
in occludin staining patterns in ileal tissues exposed to CRF
(Figure 4).
Mast Cell Degranulation is required for CRF-mediated
Increases in Paracellular Permeability in the Porcine Ileum
To determine the role of mast cell activation in CRF-mediated
intestinal permeability, we evaluated determined if CRF triggered
mast cell activation in the porcine ileum and whether blockade of
mast cell activity alterned CRF-mediated disturbances in intestinal
epithelial permeability. Exposure of porcine ileum to 0.5 mM CRF
induced mucosal mast cell degranulation as determined by
histological evidence of mast cell degranulation (Figure 5) and
quantified by the increased percentage of degranulated of
intestinal mucosal mast cells (Figure 6C). Furthermore, CRF
induced the release of mast cell tryptase (Figure 6A) and TNFa
(Figure 6B). Pre-treatment of porcine ileal tissues with the mast cell
stabilizing agent, sodium cromolyn (10
24 M), blocked CRF-
mediated mast cell degranulation (Figures 5, 6C) and increases
in FD4 flux (Figure 6D). Cromolyn also inhibited elevations in
TNFa (Figure 6D) thus indicating that CRF-induced TNFa
release was mast cell dependent. To compare the CRF response to
a known mast cell degranulation response, tissues were treated
with the mast cell degranulating compound c48/80. c48/80
induced marked mast cell degranulation (Figure 6C) and increases
in FD4 flux (Figure 6D) that were greater than CRF (p,0.05).
Blockade of TNF-a and Protease Activity Prevents CRF-
induced Gut Barrier Dysfunction
To determine if the mast cell mediators, TNF-a and MC
proteases, were responsible for CRF-mediated intestinal barrier
dysfunction in the porcine ileum, we treated porcine ileal mucosa
on Ussing chambers with a PI cocktail or porcine anti-TNF-a
prior to CRF exposure. Protease inhibitors (PI) and anti-TNF-a
(0.1 and 10 mg/mL) inhibited CRF-stimulated elevations in FD4
flux (Figure 7A–B). Under baseline condition (no CRF), PI and the
higher anti-TNF-a (10 mg/mL) reduced baseline FD4 flux
indicating the influence of proteases and TNF-a under basal
conditions.
Neuronal Activity is required for CRF-induced Gut Barrier
Dysfunction
To determine whether or not the enteric nervous system played
a critical role in CRF-mediated mast cell activation and
disturbances in intestinal epithelial permeability, tissues were
pretreated on Ussing chambers with the neuronal blocker,
tetrodotoxin (TTX) prior to CRF exposure. TTX pretreatment
Figure 1. CRF induces elevations in FD4 flux in porcine ileum. Porcine ileum was placed on Ussing Chambers and treated with CRF at
increasing concentrations (0.05, 0.1, and 0.5 mM) and the rate of FD4 flux was measured over a 180-minute period. CRF at all concentrations induced
elevations in FD4 flux (p,0.01) with the highest FD4 flux rates observed with 0.5 mM CRF. Data for each experimental treatment are expressed as
means 6 SE for n=628 pigs. Symbols (*,{) differ from other treatments by p,0.05; ANOVA.
doi:10.1371/journal.pone.0039935.g001
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(Figure 8A) and increases in FD4 flux (Figure 8B) thus indicating
an important role of enteric neural signaling in these pathways.
Discussion
A central pathophysiologic mechanism by which stress induces
intestinal diseases, including IBS and IBD, is via disturbances in
intestinal epithelial barrier function [5,19,20,21,22,23]. These
studies, utilizing an ex vivo Ussing chamber model with porcine
ileum, demonstrate that the stress peptide, CRF, triggers
disturbances in intestinal epithelial barrier function via a
mechanism that involves mast cell dependent TNF-a and protease
release and disruption of paracellular tight junctions. Furthermore,
we show that the enteric nervous system plays a critical role in
CRF-mediated mast cell activation and intestinal barrier injury.
The present studies support previous observations in rodent
models in that CRF is the key mediator triggering disturbances in
intestinal function including motility disorders and intestinal
barrier dysfunction [6,11,24,25]. Although the role of CRF in
stress-induced intestinal disturbances is well-recognized, the
precise mechanism by which CRF signals to trigger epithelial
Figure 2. CRF-induced FD4 flux is Prevented with Astressin B. CRF (0.5 mM) induced elevations in the rate of FD4 flux across the porcine ileum
mounted on Ussing chambers. Pre-treatment of ileal mucosa with Astressin B (1 mM) 30 minutes prior to CRF exposure prevented CRF-mediated
increases in FD4 flux rates. Data for each experimental treatment are expressed as means 6 SE for n=628 pigs. Symbols (*,{) differ from other
treatments by p,0.05; ANOVA.
doi:10.1371/journal.pone.0039935.g002
Figure 3. Histological appearance of CRF-treated porcine ileal
mucosa on Ussing chambers. Ileal histology (206magnification) of
hematoxylin and eosin-stained porcine ileal sections after 180 minutes
on Ussing chamber following treatment with vehicle control (A) or
0.5 mM CRF (B). Images are representative of ileal sections from n=6
pigs/treatment.
doi:10.1371/journal.pone.0039935.g003
Figure 4. Occludin localization in porcine ileum exposed to
CRF. In control (vehicle-treated) tissues (A), occludin (green) was
localized predominantly to the interepithelial tight junctions as
demonstrated by the epithelial membrane staining patterns whereas
CRF-treated tissues (B) exhibited a disrupted occluding staining pattern.
Images are representative of tissues from n=3 pigs.
doi:10.1371/journal.pone.0039935.g004
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have shown that activation of intestinal mast cells is a critical
component in stress-induced intestinal barrier disturbances
[11,26,27]. It remains unclear how CRF triggers mast cell
activation and which mast cell mediators are responsible for
triggering CRF mediated barrier changes. We show here that in
porcine ileum, CRF induces release of mast cell proteases and
TNF-a and that each of these mediators contribute significantly to
CRF-induced intestinal barrier dysfunction as pharmacologic
inhibition of protease activity and anti-TNF-a reduced CRF-
induced elevations in intestinal permeability. The mechanisms by
which mast cell proteases and TNF-a are working to induce
epithelial barrier dysfunctions are currently unclear but appear to
be mediating their effects on the paracellular tight junction as CRF
treatment disrupted the localization of the tight junction protein
occludin. It is well-known that TNF-a and proteases can trigger
epithelial barrier disruption although via different mechanisms.
TNF-a can potently enhance epithelial permeability through
increased myosin light-chain kinase (MLCK) expression and
activity [28] which alters size selectivity of the tight junction to
increase paracellular flux of uncharged macromolecules [29]. In
addition, increased TNF-a levels in vivo has recently been shown to
regulate intestinal epithelial tight junctions independent of the
actomyosin ring [30] by triggering caveolin-1 dependent endocy-
tosis of occludin that could cause loss of barrier function.
Additionally, TNF-a induces an increase of tight junction
permeability in vitro through the activation of NF-kB and the
subsequent down-regulation and alteration of ZO-1 protein
expression [28]. MC proteases such as tryptase induce barrier
dysfunction via alternate signaling mechanisms [31]. In an in vitro
cell co-culture model using the HMC-1 human mast cell line and
T84 intestinal epithelial cells, it was shown that MC derived
tryptase impaired barrier function via activation proteinase-
activated-receptor-2 (PAR-2) triggering tight junction breakdown
and increased paracellular permeability [31]. This pathway was
shown to involve B-arrestin-dependent activation of ERK 1/2,
then, regulates the reorganization of perijunctional F-actin in the
tight junctions of colonocytes, causing an increase in intestinal
permeability [31], [32]. Mice deficient in mast cell protease 4, a
homologue for human chymase, were shown to have decreased
intestinal permeability and reduced expression of claudin-3
indicating that mast cell chymase also plays an important role in
regulating intestinal permeability [33]. Given that the PI cocktail
used in the current study contained both tryptase and chymase
inhibitors, we were not able to discern which specific mast cell
proteases (tryptase and/or chymase) were responsible for CRF-
mediated intestinal barrier dysfunction.
In the present study, CRF induced changes in paracellular
permeability as indicated by FD4 flux; but had no effect on TER.
The conflicting data between paracellular flux and TER has been
observed by others [6] and may be due to activation of separate
epithelial permeability pathways by CRF. For example, TNF-a
has been shown to initiate MLCK dependent changes in size
selectivity of the tight junction to enhance paracellular flux of
uncharged macromolecules without affecting charge, while IL-13
dependent claudin-2 expression was shown to increase paracel-
lular permeability to cation flux in vitro and in vivo without altering
tight junction size selectivity [29,30]. These ‘leak’ and ‘pore’
pathways, respectively, are quickly gaining evidence for differential
regulation of paracellular permeability pathways [29,34], and
Figure 5. Histologic analysis of CRF-mediated intestinal mast cell degranulation. Treatment of porcine ileal tissues mounted on Ussing
chambers with CRF caused and increase in mast cell degranulation as determined by toluidine blue staining. Arrows indicate the release of mast cell
granules into surrounding tissues. Sodium cromolyn, a mast cell stabilizing agent, prevented CRF-induced mast cell degranulation. Figures are
representative of ileal tissue sections from n=4 pigs.
doi:10.1371/journal.pone.0039935.g005
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paracellular permeability to uncharged ions but little changes in
TER. Alternatively, disparate effects of CRF on FD4 flux and
TER may also be due to time-dependent changes in TER.
Chronic administration of CRF increases conductance and thus
decreases in TER in rodents [11] whereas our ex vivo model would
represent acute CRF effects.
Nerve-mast cell interactions have been an increasing subject of
interest due to their role in several intestinal disorders [35]. The
interplay between CRF, mast cells, and enteric nerves has been
documented in rodents [36,37] and humans [38]; however, the
nature of these interactions remains poorly understood. In the
present study, the barrier-disrupting effects of CRF were
prevented by the nerve blocker, TTX demonstrating that enteric
neural signaling is a critical element in CRF-mediated intestinal
barrier dysfunction. This important role of the enteric nervous
system in stress-induced intestinal barrier disruption has been
demonstrated previously in rodent models [6,21]; however, it
remains unclear how enteric neuronal signaling modulates this
important pathway. In our studies, we showed that enteric neural
inhibition blocked both baseline and CRF-mediated mast cell
degranulation. This suggests that enteric neural signaling may
modulate intestinal barrier function under baseline and stressed
conditions via the control of mast cell activation.
CRF receptors are expressed on enteric neurons [39,40] and
mast cells [41,42] and therefore it is difficult to delineate the
precise signaling pathways with the pharmacologic approach used
in the present study. CRF could be mediating its effect on mast cell
Figure 6. The role of mast cell activation in CRF-mediated changes in FD4 flux. Treatment of porcine ileal tissues mounted on Ussing
chambers with CRF increased mast cell degranulation indicated by the increased percentage of degranulated mast cells (C) and the increased release
of mast cell tryptase (A) and TNF-a (B). Treatment of porcine ileal tissues with cromolyn sodium 30 minutes prior to exposure to 0.5 mM CRF blocked
mast cell degranulation (C) and TNF-a release (B) and prevented CRF-mediated increases in FD4 permeability (D). c48/80 (5 mg/mL) induced marked
degranulation of mast cells (C) and increases in FD4 flux (D) that were inhibited with sodium cromolyn. Data for each FD4 flux experiments are
expressed as means 6 SE for n=628 pigs. Symbols (*,{) differ from other treatments by p,0.05; ANOVA.
doi:10.1371/journal.pone.0039935.g006
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mediators such as substance P and calcitonin gene related peptide
that in turn can trigger degranulation of mast cells [43,44].
Alternatively CRF could activate mast cells via direct CRF
receptor activation and this pathway could be influence by enteric
neural signaling. As stated above, mast cells express CRF receptor
Figure 7. Neutralization of TNF-a and protease activity inhibits CRF-induced increases in FD4 flux in porcine ileum. Pretreatment of
porcine ileum mounted on Ussing chambers with neutralizing anti-TNF-a antibody prevented CRF –induced increased in FD4 flux. Pre-treatment of
porcine ileum with a protease inhibitor (PI) cocktail reduced baseline FD4 flux values and CRF-induced increases in FD4 flux. Values represent means
SE; n=628 animals. Symbols (*,{) differ from other treatments by p,0.05.
doi:10.1371/journal.pone.0039935.g007
Figure 8. The Role of the enteric nervous system in CRF-mediated mast cell activation and FD4 flux. Toluidine blue staining of
histological sections (100 X magnification) (A) and quantitation of the % of degranulated tissue mast cells (B) in porcine ileum revealed increased
degranulation of mast cells in CRF–treated tissues. Treatment of ileal tissues with tetrodotoxin (TTX) inhibited mast cell degranulation and FD4 flux
(C) under basal and CRF-stimulated conditions and inhibited. For histological analysis, values represent means 6 SE; n=6 animals and are presented
as the percentage of total cell count per treatment at 206magnification. FD4 flux values represent means 6 SE; n=628 animals Symbols (*,{) differs
significantly by p,0.05 from vehicle control.
doi:10.1371/journal.pone.0039935.g008
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mast cell line demonstrated that CRF directly stimulates the
selective release of vascular endothelial growth factor (VEGF);
however, tryptase and TNF-a release was not induced by CRF
which in contrast to the present studies in native porcine ileal
tissues [41]. The lack of effect of CRF on tryptase or TNFa
observed in HMC1 cells by Cao et al. [41] is likely due to the
simplified cell culture conditions and therefore lack of potentially
critical co-factors that are present in native tissues. In support of
this hypothesis, Asadi et al. [45] demonstrated that pre-treatment
of the human mast cell line LAD2 with substance P induced CRF1
expression and enhanced CRF-mediated TNF-a and IL-8 release.
This suggests that neural mediators may play a crucial role in
priming the mast cell for CRF signaling; however, demonstration
of these signaling pathways in vivo have yet to be demonstrated.
Overall, we show here that in porcine ileum, CRF induces the
release of mast cell proteases and TNF-a which contribute
significantly to CRF-induced disturbances in intestinal epithelial
barrier function; furthermore these pathways are regulated by the
enteric nervous system. Given the clinical significance of these
pathways in stress-related intestinal disorders such as IBS and
IBD, a greater understanding of how these signaling pathways are
integrated during health and disease are needed.
Materials and Methods
Ethics Statement
The North Carolina State University Institutional Animal Care
and Use Committee approved all studies.
Animals and Intestinal Tissue Collection
Yorkshire x Hampshire cross-bred pigs of either sex and
between 628 weeks of age were used in this study. Prior to
experiments and tissue harvest, pigs were sedated with a
combination of xylazine (1.5 mg im) and ketamine (11 mg/kg
im) followed by euthanasia with an intravenous overdose of
pentobarbital via a catheterized ear vein. Initial sedation was used
to minimize stress before we obtained intestine for subsequent
intestinal studies. Segments of ileum were harvested immediately
after euthanasia and prepared for Ussing chamber studies.
Chemicals and Reagents
Rat/human CRF (0.01–0.5 mM) and Astressin B (1 mM) were
obtained from The Salk Institute, La Jolla, CA. CRF doses were
based on comparable doses of CRF used in several experiments
utilizing cell culture models [41,45,46] and physiological ranges
found in peripheral tissues including primary rat adrenals [47] and
human endometria [48]. Cromolyn sodium, porcine anti-TNF-a
neutralizing antibody, protease inhibitor cocktail, c48/80, and
tetrodotoxin (TTX) were obtained from Sigma Chemical. The PI
cocktail contained the chymase inhibitor Soybean Trypsin
Inhibitor (100 mg/mL) and the tryptase inhibitor Aprotinin
(Sigma, 10 mM).
Ussing Chamber Experiment
Ileal mucosa was stripped from the seromuscular layer in
oxygenated (95% O2–5% CO2) Ringer solution (in mmol/l:
154 Na
+, 6.3 K
+, 137 Cl
2, 0.3 H2PO4
-, 1.2 Ca
2+, 0.7 Mg
2+,2 4
HCO3
2; pH 7.4). Tissues were then mounted in 1.13 cm
2
aperture Ussing chambers, as described in previous study [5,49].
Tissues were bathed on the serosal and mucosal sides with 10 mL
of Ringer solution. The serosal bathing solution contained 10 mM
glucose, which was osmotically balanced on the mucosal side with
10 mM mannitol. Bathing solutions were oxygenated (95% O2–
5% CO2) and circulated in water-jacketed reservoirs maintained at
37uC. The spontaneous potential difference (PD) was measured
using Ringer-agar bridges connected to calomel electrodes, and
the PD was short-circuited through Ag-AgCl electrodes using a
voltage clamp that corrected for fluid resistance. Tissues were
maintained in the short-circuited state, except for brief intervals to
record the open-circuit PD. Transepithelial electrical resistance
(TER; V?cm
2) was calculated from the spontaneous PD and short-
circuit current (Isc), as previously described [50]. After a 30-min
equilibration period on Ussing chambers, TER was recorded at
15-min intervals over a 4-hr period and then averaged to derive
the basal TER values for each experimental treatment.
Mucosal-to-serosal Fluxes of FITC-labeled Dextran
Mucosal-to-serosal fluxes of (FITC)-dextran (4 kDa; Sigma-
Aldrich, St. Louis, MO) were performed at the same time as
TER was measured. After a 15-min period on Ussing chambers,
FITC Dextran (0.25 mM) was added to the mucosal side of
Ussing chamber-mounted tissues. The FD4 was allowed to
equilibrate for 15 min after which 100 mL samples (in triplicate)
were taken from the serosal side of tissues at 30-minute intervals
and transferred into a 96 well assay plate. The presence of FD4
fluorescence intensity of each sample was measured by fMax
Fluorescence Microplate Reader (Molecular Devices, Sunnyvale,
CA) and concentrations were determined from standard curves
generated by serial dilution of FD4. FD4 flux was measured for
180 minutes post-CRF exposure and presented as the rate of
FD4 flux (mg/min).
Experimental Protocol
After mounting on Ussing chambers, ileal tissues were allowed
to equilibrate for a 15–30 minute period until tissue TER and Isc
values stabilized. Thirty minutes prior to CRF exposure,
Pharmacologic antagonists (Astressin B, cromolyn, PI, anti-TNFa,
and TTX) were added to the serosal side of ileal mucosa, where
the actions of these compounds are expected to exert direct effects
on submucosal target cells. CRF was added to the serosal chamber
and TER and FD4 flux were measured over a 180-min period.
Histological Examination
At the end of the Ussing chamber experiments, ileal tissues fixed
in 10% neutral buffered formalin, paraffin-embedded, and stained
with hematoxylin and eosin for histological analysis. Tissues were
visualized for changes in intestinal pathology as a result of
experimental agonist treatments (Meiji Microscope Solutions,
Model OMFL400).
Mast Cell Histological Analysis Counts
Frozen sections of ileum (10 mm thick) were prepared and then
fixed for 1 h in Carnoy’s fixative (60% ethanol-30% chloroform-
10% glacial acetic acid). Sections were then stained for 45 min at
room temperature with 0.5% toluidine blue in 0.5 N HCl in PBS.
Mast cell counts were conducted on five different fields per slide
from n=4 pigs per treatment group. Data is presented as
percentage of mast cells exhibiting degranulation. All histological
analyses were performed by at least 2 reviewers who were blinded
to experimental treatments.
Measurement of TNF-a
Supernatant from the serosal bathing solution of Ussing
Chambers was collected at time 240 min (end of experiment) for
analysis of TNF-a using a commercial ELISA kit (R&D Systems)
according to manufacturer’s instructions. Samples were frozen
Mechanisms of CRF-Induced Intestinal Dysfunction
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280uC until assay.
Tryptase Assay of Ileal Culture Supernatant
Ileal segments weighing 0.05 g were dissected into small
fragments, weighed, and placed into 24 well culture plates with
cRPMI +0.5% gentamicin. Tissues were incubated with CRF
receptor agonist treatments for 180 minutes before supernatant
was removed, centrifuged, and stored at 220uC until assay.
Supernatant samples were analyzed for tryptase content using
Thiobenzyl Ester Substrate assay as previously described [51].
Immunofluorescence and Confocal Analysis
Porcine ileal sections were stained with the primary antibody as
indicated by the manufacturer’s instructions. Confocal images
were obtained with a 3-Laser Nikon Confocal Laser Scanning
Instrument (Nikon Instruments). Images were obtained using EZ-
C1 Nikon software (Silver Version 2.01). Threshold values were
determined using the appropriate isotype-matched controls. A
channel series approach was used to ensure no spectral overlap
between fluorescent signals. Primary antibodies include occluding
(mouse-anti-occludin, Invitrogen), 1:1000. Secondary antibodies
used include Fab-antibodies, Jackson Labs Inc (donkey-anti-mouse
FITC), 1:1000. Nuclei were visualized with To-Pro-3 iodide 642/
661 (Invitrogen) 1:1000.
Statistical Analyses
Data are reported as means 6 SE based on the experimental
number (n). Data were analyzed by using a standard one-way
ANOVA (Sigmastat, Jandel Scientific, San Rafael, CA). A post
hoc Fisher’s least significant difference (LSD) test was used to
determine differences between treatments following ANOVA. MC
counts were analyzed using Mann-Whitney test, and differences
considered significant if p,0.05.
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